Anthracyclines at Antitumor Antibiotics

Mahahalagang Punto

• Ang anthracyclines (halimbawa doxorubicin, daunorubicin, epirubicin) ay humahadlang sa topoisomerase upang pigilan ang DNA replication at mag-trigger ng pagkamatay ng tumor cells.
• Ang class na ito ay high-risk vesicant group; ang extravasation ay maaaring magdulot ng severe tissue necrosis.
• Ang cumulative cardiotoxicity ay pangunahing dose-limiting toxicity; kailangan ang lifetime-dose limits at serial cardiac monitoring.
• Karaniwang treatment-limiting adverse effects ang myelosuppression, nausea/vomiting, alopecia, at mucositis.
• Ang doxorubicin ay maaaring magdulot ng pansamantalang red-orange discoloration ng ihi at body fluids pagkatapos ng treatment.

Mechanism of Action

Ang anthracyclines at kaugnay na antitumor antibiotics ay humahadlang sa DNA replication sa pamamagitan ng inhibition ng topoisomerase. Hinaharangan nito ang DNA strand processing habang cell division at nagtataguyod ng apoptosis sa rapidly dividing tumor cells.

Mga Karaniwang Gamot

• Doxorubicin
• Daunorubicin
• Epirubicin
• Bleomycin (naka-classify bilang antitumor antibiotic at mino-monitor para sa pulmonary toxicity risk)

Nursing Considerations

• I-verify ang baseline at interval cardiac evaluation (kabilang ang left ventricular ejection fraction) bago at habang anthracycline therapy.
• I-track ang cumulative lifetime dosing, dahil tumataas ang heart-failure risk sa paulit-ulit na exposure (halimbawa humigit-kumulang 550 mg/m2 lifetime limits para sa doxorubicin/daunorubicin regimens).
• Bantayan ang maagang palatandaan ng cardiotoxicity: dyspnea, edema, fatigue, reduced activity tolerance, chest discomfort, at bagong rhythm concerns.
• Ituring ang mga gamot na ito bilang vesicants: kumpirmahin ang maaasahang vascular access, madalas na i-monitor ang site patency, at sundin agad ang extravasation protocol kung may burning/swelling.
• Suriin ang CBC trends para sa myelosuppression at agad i-escalate ang neutropenic fever, bleeding cues, o symptomatic anemia.
• I-monitor ang severe nausea/vomiting, mucositis, at cumulative organ toxicity patterns.

Adverse Effects at Contraindications

• Hematologic: myelosuppression, infection risk, bleeding risk.
• Cardiac: acute at delayed cardiotoxicity; tumataas ang risk sa cumulative exposure.
• GI and mucosal: nausea/vomiting, stomatitis/mucositis.
• Dermatologic: alopecia, skin o nail hyperpigmentation.
• Pulmonary (selected agents such as bleomycin): interstitial injury/fibrosis risk.
• Kabilang sa contraindications ang severe preexisting cardiac dysfunction at inadequate cardiac reserve para sa planadong anthracycline exposure.

Health Teaching

• I-report agad ang fever, sore throat, unusual bruising/bleeding, mouth ulcers, o persistent vomiting.
• I-report agad ang shortness of breath, chest pain, edema, o mabilis na hindi maipaliwanag na weight gain.
• Unawain na maaaring mangyari ang pansamantalang red-orange urine o body-fluid discoloration pagkatapos ng doxorubicin.
• Iwasan ang pagbubuntis habang therapy at sundin ang contraception guidance mula sa oncology team.
• Panatilihin ang lahat ng naka-iskedyul na lab at cardiac follow-up appointments.

Related Concepts

• vesicants - Class-level extravasation injury risk at antidote pathways.
• Infiltration at extravasation - Agarang bedside response steps para sa pinaghihinalaang leakage.
• Medication-induced cardiopulmonary adverse effects - Balangkas ng cumulative cardiotoxic monitoring.
• Leukopenia at neutropenia - Infection-risk escalation habang marrow suppression.
• Thrombocytopenia: panganib ng pagdurugo at pamamahala - Bleeding-risk surveillance sa cytopenic phases.

Self-Check

1. Bakit kailangan ang cumulative-dose tracking sa anthracycline therapy?
2. Anong bedside findings ang dapat mag-trigger ng agarang extravasation response habang infusion?
3. Aling sintomas ang nangangailangan ng urgent escalation para sa posibleng anthracycline cardiotoxicity?